Breaking News Headlines Today

News from Optimum Strategic Communications

See all of Optimum Strategic Communications news coverage in one place. Discover how Optimum Strategic Communications’s media bias informs their coverage and compare with thousands of other news outlets.

Overall, we’ve indexed 53 stories from Optimum Strategic Communications over the past 3 months.

Optimum Strategic Communications’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Optimum Strategic Communications’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Optimum Strategic Communications

Where is Optimum Strategic Communications located?Optimum Strategic Communications's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

One Biosciences Announces €15 Million Series A Financing to Advance Clinical Single Cell Profiling

Funding will be used to establish the clinical utility of OneMap™, a proprietary artificial intelligence (AI) driven single cell transcriptomic oncology platform, to guide treatment decisions, patient selection, therapy development, and optimize clinical trialsProceeds will also help scale strategic partnerships…See the Story

Xeltis Reports Preliminary Data For Coronary Artery Bypass Conduit - Data Intelligence

The EU study aims to assess the Xabg technology in patients with multi-vessel atherosclerotic coronary artery disease who are scheduled for elective CABG surgery. Credit: Photoroyalty / Shutterstock.com. Xeltis has reported positive preliminary data for its Xabg coronary artery bypass conduit (CABG) in a clinical trial that is underway at various European Union (EU) sites. The data from the trial indicated positive safety and patency for individ…European Union See the Story

Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business – Optimum Strategic CommunicationsLink to: Have we reached “peak drugs pricing”?Scroll to top

Clinical trial with ATAC candidate HDP-101 in multiple myeloma shows promising data Cohort 7 of the Phase I dose escalation study with HDP-101 safe and well tolerated; Cohort 8 started First patient in clinical study dosed with the second ATAC candidate HDP-102 in the non-Hodgkin lymphoma (NHL) indication Amendment of contract with HealthCare Royalty; payment of […]Heidelberg, Germany · Heidelberg Read Article

Weekly roundup: Dealmaker’s insights, a new CEO, plus… the UK Government’s got a plan! – Optimum Strategic CommunicationsLink to: Can the UK government kick-start the country’s life science industry?Scroll to top

Jacob Falck Hansen appointed as Chief Executive Officer of Vesper Bio Vesper Bio a clinical stage biotech developing an oral therapy for frontotemporal dementia, announces the appointment of Jacob Falck Hansen as Chief Executive Officer. Jacob brings more than 15 years of leadership experience from the pharmaceutical and biotech industry. He is a Partner at […]Dementia · United Kingdom Read Article

Várhelyi Races to Deliver ‘Major Overhaul’ of EU Health Laws in 2025

100% Left coverage: 1 sources

The EU’s health commissioner says there’s “no time to lose” as he lays out a raft of plans in the Life Sciences Strategy for sectors that need urgent assistance.European Union See the Story

Jacob Falck Hansen appointed as Chief Executive Officer of Vesper Bio – Optimum Strategic CommunicationsLink to: Weekly roundup: Wins in and out of the clinicScroll to top

Copenhagen, Denmark, 01 July 2025 – Vesper Bio ApS (“Vesper” or “the Company”), a clinical stage biotech developing an oral therapy for frontotemporal dementia, today announces the appointment of Jacob Falck Hansen as Chief Executive Officer (CEO). Jacob Falck Hansen brings more than 15 years of leadership experience from the pharmaceutical and biotech industry. He […]Pharma · Denmark Read Article

Weekly roundup: Wins in and out of the clinic – Optimum Strategic CommunicationsLink to: Challenge accepted: New funding for ambitious projects within biomanufacturing, cardiometabolic diseases, and artificial intelligenceScroll to top

Curve Therapeutics Co-Founder and CSO Professor Ali Tavassoli awarded the Royal Society of Chemistry’s Interdisciplinary Prize Curve Therapeutics proudly announced that Professor Ali Tavassoli, its Co-Founder and Chief Scientific Officer, has been awarded the Interdisciplinary Prize by the Royal Society of Chemistry in recognition of his brilliance in research and innovation, and contribution to scientific […]Read Article

Challenge accepted: New funding for ambitious projects within biomanufacturing, cardiometabolic diseases, and artificial intelligence – Optimum Strategic CommunicationsLink to: Hot topic: Midsummer is here – winter is comingScroll to top

The 2025 Novo Nordisk Foundation Challenge Programme awards DKK 479 million to nine innovative projects that advance health and sustainability through cooperation between researchers from all over the globe, including Denmark, Sweden, The Netherlands, Belgium, Germany, Australia, and the USA. Read more…Artificial Intelligence · Denmark Read Article

STORM Therapeutics Appoints Veteran Cancer Drug Developer Dr. Eric Martin as Chief Development Officer

100% Center coverage: 1 sources

CAMBRIDGE, England, June 26, 2025 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announced the appointment of accomplished cancer biologist Dr. Eric Martin, PhD, as Chief Development Officer…England · England See the Story

News from Optimum Strategic Communications

News from Optimum Strategic Communications

Information about Optimum Strategic Communications

Media Bias Ratings

Factuality

Ownership

Top Optimum Strategic Communications News

Denmark Launches QuNorth to Build Magne, World's Most Powerful Quantum Computer

Actithera Joins Radiopharmaceutical Boom with $75.5M Series A - Boston ...

One Biosciences Announces €15 Million Series A Financing to Advance Clinical Single Cell Profiling

Xeltis Reports Preliminary Data For Coronary Artery Bypass Conduit - Data Intelligence

Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business – Optimum Strategic CommunicationsLink to: Have we reached “peak drugs pricing”?Scroll to top

Weekly roundup: Dealmaker’s insights, a new CEO, plus… the UK Government’s got a plan! – Optimum Strategic CommunicationsLink to: Can the UK government kick-start the country’s life science industry?Scroll to top

Várhelyi Races to Deliver ‘Major Overhaul’ of EU Health Laws in 2025

Jacob Falck Hansen appointed as Chief Executive Officer of Vesper Bio – Optimum Strategic CommunicationsLink to: Weekly roundup: Wins in and out of the clinicScroll to top

Weekly roundup: Wins in and out of the clinic – Optimum Strategic CommunicationsLink to: Challenge accepted: New funding for ambitious projects within biomanufacturing, cardiometabolic diseases, and artificial intelligenceScroll to top

Challenge accepted: New funding for ambitious projects within biomanufacturing, cardiometabolic diseases, and artificial intelligence – Optimum Strategic CommunicationsLink to: Hot topic: Midsummer is here – winter is comingScroll to top

STORM Therapeutics Appoints Veteran Cancer Drug Developer Dr. Eric Martin as Chief Development Officer

Similar News Topics

Topics Most Covered by Optimum Strategic Communications

Sources Covering Similar Topics

Breaking News Topics Related to Optimum Strategic Communications